Monjaro weight loss drug hits Indian market
Eli Lilly has launched its best-selling diabetes and weight loss drug Monjaro in India, beating rival Novo Nordisk in the race to enter the world’s most populous country, which is grappling with rising obesity and diabetes rates.
The once-weekly injectable Monjaro, approved by India’s drug regulator, is priced at Rs 4,375 ($50.67) for a 5-mg vial and Rs 3,500 ($40.54) for a 2.5-mg vial, with the highest dose being 15 mg.
Global sales of Monjaro have exceeded $20 billion since its initial launch in the US in 2022.
